{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T18:48:01Z","timestamp":1787597281739,"version":"build-2736575974"},"reference-count":119,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["OMI\/10\/2022\/ECD"],"award-info":[{"award-number":["OMI\/10\/2022\/ECD"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Manipal Academy of Higher Education, Manipal"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:italic>Helicobacter pylori<\/jats:italic>\n                    (\n                    <jats:italic>H. pylori<\/jats:italic>\n                    ) infection is a global health problem that affects more than half of the world population and leads to gastrointestinal disorders such as gastric ulcer, duodenal ulcer and gastric cancer. The available treatment options are inefficient because of patient non-adherence to the regimen due to the polypharmacy approach of treating\n                    <jats:italic>H. pylori<\/jats:italic>\n                    over longer periods. The bio-availability of antibiotics at the gastric mucosa, where the organism resides, is also a major concern. The continuous adaptation of bacteria such as genetic mutation toward beta-lactamase, macrolide and nitroimidazole group of antibiotics and structural barriers such as biofilm or efflux pumps contributes to the decreased efficacy of the antibiotics. These challenges ultimately result in antibiotic resistance. This review discusses the regional disparity in\n                    <jats:italic>H. pylori<\/jats:italic>\n                    infection management and the trend in anti-microbial resistance worldwide. To address these challenges, novel treatment approaches are being explored, ranging from clinically and pre-clinically supported strategies to those still at a conceptual stage, among which gastro-retentive drug delivery, nano-formulation and non-antibiotic therapies are gaining attention worldwide. In conclusion, we suggest effective region-specific management of\n                    <jats:italic>H. pylori<\/jats:italic>\n                    infection with evidence-based emerging treatment strategies to improve eradication outcomes and mitigate anti-microbial resistance.\n                  <\/jats:p>","DOI":"10.1007\/s12664-026-02005-4","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T10:52:56Z","timestamp":1781261576000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Helicobacter pylori eradication in the face of escalating anti-microbial resistance: Geographic heterogeneity and emerging treatment strategies"],"prefix":"10.1007","author":[{"given":"Moumita","family":"Saha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiran","family":"Shetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basavaraj","family":"Poojar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balaji","family":"Musunuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagalakshmi","family":"Narasimhaswamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5341-0981","authenticated-orcid":false,"given":"Sudheer","family":"Moorkoth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"issue":"3","key":"2005_CR1","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1128\/CMR.00054-05","volume":"19","author":"JG Kusters","year":"2006","unstructured":"Kusters JG, Van Vliet AHM, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev. 2006;19:449\u201390. https:\/\/doi.org\/10.1128\/CMR.00054-05.","journal-title":"Clin Microbiol Rev"},{"issue":"8","key":"2005_CR2","doi-asserted-by":"publisher","first-page":"72","DOI":"10.23750\/abm.v89i8-S.7947","volume":"89","author":"S Kayali","year":"2018","unstructured":"Kayali S, Manfredi M, Gaiani F, et al. Helicobacter pylori, transmission routes and recurrence of infection: state of the art. Acta Bio Med Atenei Parmensis. 2018;89:72. https:\/\/doi.org\/10.23750\/abm.v89i8-S.7947.","journal-title":"Acta Bio Med Atenei Parmensis"},{"issue":"1","key":"2005_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s40792-020-01081-8","volume":"7","author":"T Yokoyama","year":"2021","unstructured":"Yokoyama T, Tanaka T, Harada S, et al. A case of gastric and duodenal mucosa-associated lymphoid tissue lymphoma with multiple gastric cancers: a case report. Surg Case Rep. 2021;7:30. https:\/\/doi.org\/10.1186\/s40792-020-01081-8.","journal-title":"Surg Case Rep"},{"key":"2005_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms12010222","author":"A Ali","year":"2024","unstructured":"Ali A, AlHussaini KI. Helicobacter pylori: a contemporary perspective on pathogenesis, diagnosis and treatment strategies.\u00a0Microorganisms. 2024;12:222. https:\/\/doi.org\/10.3390\/microorganisms12010222.","journal-title":"Microorganisms"},{"issue":"4","key":"2005_CR5","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1128\/CMR.00011-10","volume":"23","author":"LE Wroblewski","year":"2010","unstructured":"Wroblewski LE, Peek RM, Wilson KT. Helicobacter pylori and gastric cancer: factors that modulate disease risk. Clin Microbiol Rev. 2010;23:713. https:\/\/doi.org\/10.1128\/CMR.00011-10.","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"2005_CR6","doi-asserted-by":"publisher","first-page":"201","DOI":"10.4103\/1319-3767.54743","volume":"1","author":"B Salih","year":"2009","unstructured":"Salih B. Helicobacter pylori infection in developing countries: the burden for how long? Saudi J Gastroenterol. 2009;1:201\u20137. https:\/\/doi.org\/10.4103\/1319-3767.54743.","journal-title":"Saudi J Gastroenterol"},{"key":"2005_CR7","doi-asserted-by":"publisher","unstructured":"Zamani M, Ebrahimtabar F, Zamani V, et al. Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther. 2018;47:868\u201376. https:\/\/doi.org\/10.1111\/apt.14561.","DOI":"10.1111\/apt.14561"},{"key":"2005_CR8","doi-asserted-by":"publisher","unstructured":"Borka Balas R, Meli\u021b LE, M\u0103rginean CO. Worldwide prevalence and risk factors of Helicobacter pylori infection in children.\u00a0Children (Basel). 2022;9:1359. https:\/\/doi.org\/10.3390\/children9091359.","DOI":"10.3390\/children9091359"},{"key":"2005_CR9","doi-asserted-by":"publisher","unstructured":"Boutayeb A. The impact of infectious diseases on the development of Africa. Handbook of Disease Burdens and Quality of Life Measures. 2010;1171. https:\/\/doi.org\/10.1007\/978-0-387-78665-0_66","DOI":"10.1007\/978-0-387-78665-0_66"},{"issue":"26","key":"2005_CR10","doi-asserted-by":"publisher","first-page":"3226","DOI":"10.3748\/wjg.v16.i26.3226","volume":"16","author":"NR Hussein","year":"2010","unstructured":"Hussein NR. Helicobacter pylori and gastric cancer in the Middle East: a new enigma? World J Gastroenterol. 2010;16:3226\u201334. https:\/\/doi.org\/10.3748\/wjg.v16.i26.3226.","journal-title":"World J Gastroenterol"},{"key":"2005_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12837","author":"A Kowada","year":"2021","unstructured":"Kowada A, Asaka M. Economic and health impacts of introducing Helicobacter pylori eradication strategy into national gastric cancer policy in Japan: A cost-effectiveness analysis.\u00a0Helicobacter. 2021;26:e12837. https:\/\/doi.org\/10.1111\/hel.12837.","journal-title":"Helicobacter"},{"key":"2005_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12886","author":"A Kowada","year":"2022","unstructured":"Kowada A, Asaka M. Economic and health impacts of Helicobacter pylori eradication strategy for the treatment of peptic ulcer disease: A cost-effectiveness analysis.\u00a0Helicobacter. 2022;27:e12886. https:\/\/doi.org\/10.1111\/hel.12886.","journal-title":"Helicobacter"},{"key":"2005_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2023.1128497","author":"RI Dasc\u0103lu","year":"2023","unstructured":"Dasc\u0103lu RI, Bolocan A, P\u0103duaru DN, et al. Multidrug resistance in Helicobacter pylori infection.\u00a0Front Microbiol. 2023;14:1128497. https:\/\/doi.org\/10.3389\/fmicb.2023.1128497.","journal-title":"Front Microbiol"},{"key":"2005_CR14","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/4710964","volume":"2022","author":"H Yang","year":"2022","unstructured":"Yang H, Guan L, Hu B. Detection and treatment of Helicobacter pylori: problems and advances. Gastroenterol Res Pract. 2022;2022:4710964. https:\/\/doi.org\/10.1155\/2022\/4710964.","journal-title":"Gastroenterol Res Pract"},{"issue":"1","key":"2005_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/hel.13057","volume":"29","author":"S Dutta","year":"2024","unstructured":"Dutta S, Jain S, Das K, Verma P, Som A, Das R. Primary antibiotic resistance of Helicobacter pylori in India over the past two decades: a systematic review. Helicobacter. 2024;29:e13057. https:\/\/doi.org\/10.1111\/hel.13057.","journal-title":"Helicobacter"},{"issue":"40","key":"2005_CR16","doi-asserted-by":"publisher","first-page":"11221","DOI":"10.3748\/wjg.v21.i40.11221","volume":"21","author":"YK Wang","year":"2015","unstructured":"Wang YK, Kuo FC, Liu CJ, et al. Diagnosis of Helicobacter pylori infection: Current options and developments. World J Gastroenterol. 2015;21:11221-35. https:\/\/doi.org\/10.3748\/wjg.v21.i40.11221.\u00a0","journal-title":"World J Gastroenterol: WJG"},{"key":"2005_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12020191","author":"A Elbehiry","year":"2023","unstructured":"Elbehiry A, Marzouk E, Aldubaib M, et al. Helicobacter pylori infection: current status and future prospects on diagnostic, therapeutic and control challenges.\u00a0Antibiotics (Basel). 2023;12:191. https:\/\/doi.org\/10.3390\/antibiotics12020191.","journal-title":"Antibiotics"},{"issue":"19","key":"2005_CR18","doi-asserted-by":"publisher","first-page":"6349","DOI":"10.12998\/wjcc.v10.i19.6349","volume":"10","author":"JH Cho","year":"2022","unstructured":"Cho JH, Jin SY. Current guidelines for Helicobacter pylori treatment in East Asia 2022: differences among China, Japan, and South Korea. World J Clin Cases. 2022;10:6349\u201359. https:\/\/doi.org\/10.12998\/wjcc.v10.i19.6349.","journal-title":"World J Clin Cases"},{"key":"2005_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/ph16111615","author":"G Muteeb","year":"2023","unstructured":"Muteeb G, Rehman MT, Shahwan M, Aatif M. Origin of antibiotics and antibiotic resistance, and their impacts on drug development: A narrative review.\u00a0Pharmaceuticals (Basel). 2023;16:1615. https:\/\/doi.org\/10.3390\/ph16111615.","journal-title":"Pharmaceuticals"},{"issue":"9","key":"2005_CR20","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.14309\/ajg.0000000000002968","volume":"119","author":"WD Chey","year":"2024","unstructured":"Chey WD, Howden CW, Moss SF, et al. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2024;119:1730\u201353. https:\/\/doi.org\/10.14309\/ajg.0000000000002968.","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"2005_CR21","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3748\/wjg.v20.i3.665","volume":"20","author":"A Federico","year":"2014","unstructured":"Federico A, Gravina AG, Miranda A, Loguercio C, Romano M. Eradication of Helicobacter pylori infection: which regimen first?\u00a0World J Gastroenterol. 2014;20:665-72. https:\/\/doi.org\/10.3748\/wjg.v20.i3.665.","journal-title":"World Journal of Gastroenterology\u202f: WJG"},{"key":"2005_CR22","doi-asserted-by":"publisher","unstructured":"Jonaitis P, Nyssen OP, Saracino IM, et al. Comparison of the management of Helicobacter pylori infection between the older and younger European populations. Sci Rep. 2023;13:17235. https:\/\/doi.org\/10.1038\/s41598-023-43287-4","DOI":"10.1038\/s41598-023-43287-4"},{"issue":"1","key":"2005_CR23","doi-asserted-by":"publisher","first-page":"74","DOI":"10.51821\/86.1.11327","volume":"86","author":"R Garc\u00e9s-Duran","year":"2023","unstructured":"Garc\u00e9s-Duran R, Kindt S, Kotilea K, et al. Belgian consensus for Helicobacter pylori management 2023.\u00a0Acta Gastroenterol Belg. 2023;86:74-91. https:\/\/doi.org\/10.51821\/86.1.11327.","journal-title":"Acta Gastroenterol Belg"},{"key":"2005_CR24","unstructured":"RACGP - Helicobacter pylori eradication \u2013 an update on the latest therapies [Internet]. [cited 2026 Mar 18]. Available from: https:\/\/www.racgp.org.au\/afp\/2014\/may\/helicobacter-pylori-eradication"},{"issue":"1","key":"2005_CR25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/ggh3.12843","volume":"7","author":"N Aumpan","year":"2023","unstructured":"Aumpan N, Mahachai V, Vilaichone R. Management of Helicobacter pylori infection. JGH Open. 2023;7:3\u201315. https:\/\/doi.org\/10.1002\/ggh3.12843.","journal-title":"JGH Open"},{"key":"2005_CR26","doi-asserted-by":"publisher","unstructured":"Singh SP, Ahuja V, Ghoshal UC, et al. Management of Helicobacter pylori infection: The Bhubaneswar Consensus Report of the Indian Society of Gastroenterology. Indian J Gastroenterol. 2021;40:420\u201344. https:\/\/doi.org\/10.1007\/s12664-021-01186-4.","DOI":"10.1007\/s12664-021-01186-4"},{"key":"2005_CR27","doi-asserted-by":"publisher","DOI":"10.1177\/17562848211064080","volume":"14","author":"A Shiotani","year":"2021","unstructured":"Shiotani A, Roy P, Lu H, Graham DY. Helicobacter pylori diagnosis and therapy in the era of antimicrobial stewardship. Therap Adv Gastroenterol. 2021;14:17562848211064080. https:\/\/doi.org\/10.1177\/17562848211064080.","journal-title":"Therap Adv Gastroenterol"},{"issue":"4","key":"2005_CR28","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v8.i4.341","volume":"8","author":"SF Zaidi","year":"2016","unstructured":"Zaidi SF. Helicobacter pylori associated Asian enigma: Does diet deserve distinction? World J Gastrointest Oncol. 2016;8:341\u201350. https:\/\/doi.org\/10.4251\/wjgo.v8.i4.341.","journal-title":"World J Gastrointest Oncol"},{"issue":"1","key":"2005_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-63982-0","volume":"14","author":"Q Abdoh","year":"2024","unstructured":"Abdoh Q, Alnees M, Kharraz L, et al. Prevalence of Helicobacter pylori resistance to certain antibiotics at An-Najah University Hospital: a cross-sectional study. Sci Rep. 2024;14:14542. https:\/\/doi.org\/10.1038\/s41598-024-63982-0.","journal-title":"Sci Rep"},{"key":"2005_CR30","unstructured":"Guidelines | World Gastroenterology Organisation [Internet]. [cited 2026 Mar 18]. Available from: https:\/\/www.worldgastroenterology.org\/guidelines"},{"issue":"6","key":"2005_CR31","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3748\/wjg.v20.i6.1517","volume":"20","author":"M Song","year":"2014","unstructured":"Song M, Ang TL. Second and third line treatment options for Helicobacter pylori eradication.\u00a0World J Gastroenterol. 2014;20:1517-28.\u00a0https:\/\/doi.org\/10.3748\/wjg.v20.i6.1517.","journal-title":"World Journal of Gastroenterology\u202f: WJG"},{"key":"2005_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/ijms262311408","author":"K Namikawa","year":"2025","unstructured":"Namikawa K, Purisevic FL, Thorsteinsson JB, Bjornsson ES. Helicobacter pylori across continents: contrasts in epidemiology, genetics, clinical impact, and management between East and West.\u00a0Int J Mol Sci. 2025;26:11408. https:\/\/doi.org\/10.3390\/ijms262311408.","journal-title":"Int J Mol Sci"},{"key":"2005_CR33","unstructured":"Howden CW, Chey WD, Vakil NB. Clinical rationale for confirmation testing after treatment of Helicobacter pylori infection: Implications of rising antibiotic resistance.\u00a0Gastroenterol Hepatol (N Y). 2014;10 7 Suppl 3:1\u201319."},{"key":"2005_CR34","doi-asserted-by":"publisher","unstructured":"Caldas M, P\u00e9rez-Aisa \u00c1, Castro-Fern\u00e1ndez M, et al. European registry on Helicobacter pylori management: Effectiveness of first and second-line treatment in Spain.\u00a0Antibiotics (Basel). 2020;10:13. https:\/\/doi.org\/10.3390\/antibiotics10010013.","DOI":"10.3390\/antibiotics10010013"},{"issue":"1","key":"2005_CR35","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2147\/CEG.S25419","volume":"5","author":"JP Gisbert","year":"2012","unstructured":"Gisbert JP, Calvet X. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori.\u00a0Clin Exp Gastroenterol. 2012;5:23-34.\u00a0https:\/\/doi.org\/10.2147\/CEG.S25419.","journal-title":"Clin Exp Gastroenterol"},{"issue":"1","key":"2005_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-023-02707-5","volume":"23","author":"S Fekadu","year":"2023","unstructured":"Fekadu S, Engiso H, Seyfe S, et al. Effectiveness of eradication therapy for Helicobacter pylori infection in Africa: a systematic review and meta-analysis. BMC Gastroenterol. 2023;23:55. https:\/\/doi.org\/10.1186\/s12876-023-02707-5.","journal-title":"BMC Gastroenterol"},{"key":"2005_CR37","doi-asserted-by":"publisher","DOI":"10.5694\/mja16.00104","author":"H Mitchell","year":"2016","unstructured":"Mitchell H, Katelaris P. Epidemiology, clinical impacts and current clinical management of Helicobacter pylori infection. Med J Aust. 2016;204:376-80. https:\/\/doi.org\/10.5694\/mja16.00104.","journal-title":"Med J Aust"},{"issue":"2","key":"2005_CR38","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.dld.2014.10.009","volume":"47","author":"JP Gisbert","year":"2015","unstructured":"Gisbert JP, Romano M, Molina-Infante J, et al. Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatments. Dig Liver Dis. 2015;47:108\u201313. https:\/\/doi.org\/10.1016\/j.dld.2014.10.009.","journal-title":"Dig Liver Dis"},{"issue":"1","key":"2005_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s13099-025-00704-5","volume":"17","author":"RG Elbaiomy","year":"2025","unstructured":"Elbaiomy RG, Luo X, Guo R, et al. Antibiotic resistance in Helicobacter pylori: a genetic and physiological perspective. Gut Pathog. 2025;17:35. https:\/\/doi.org\/10.1186\/s13099-025-00704-5.","journal-title":"Gut Pathog"},{"key":"2005_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s13099-021-00438-0","author":"B Attaran","year":"2021","unstructured":"Attaran B, Salehi N, Ghadiri B, et al. The penicillin binding protein 1A of Helicobacter pylori, its amoxicillin binding site and access routes. Gut Pathog. 2021;13:43. https:\/\/doi.org\/10.1186\/s13099-021-00438-0.","journal-title":"Gut Pathog"},{"issue":"1","key":"2005_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/1476-0711-2-11","volume":"2","author":"ML Ribeiro","year":"2003","unstructured":"Ribeiro ML, Vitiello L, Miranda MCB, et al. Mutations in the 23S rRNA gene are associated with clarithromycin resistance in Helicobacter pylori isolates in Brazil. Ann Clin Microbiol Antimicrob. 2003;2:11. https:\/\/doi.org\/10.1186\/1476-0711-2-11.","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"1","key":"2005_CR42","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/j.1523-5378.2011.00912.x","volume":"17","author":"E Rimbara","year":"2012","unstructured":"Rimbara E, Noguchi N, Kawai T, Sasatsu M. Fluoroquinolone resistance in Helicobacter pylori: role of mutations at position 87 and 91 of GyrA on the level of resistance and identification of a resistance conferring mutation in GyrB. Helicobacter. 2012;17:36\u201342. https:\/\/doi.org\/10.1111\/j.1523-5378.2011.00912.x.","journal-title":"Helicobacter"},{"key":"2005_CR43","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jgar.2019.01.008","volume":"17","author":"B Marques","year":"2019","unstructured":"Marques B, Donato MM, Cardoso O, Luxo C, Martinho A, Almeida N. Study of rdxA and frxA genes mutations in metronidazole-resistant and -susceptible Helicobacter pylori clinical isolates from the central region of Portugal. J Glob Antimicrob Resist. 2019;17:300\u20134. https:\/\/doi.org\/10.1016\/j.jgar.2019.01.008.","journal-title":"J Glob Antimicrob Resist"},{"issue":"9","key":"2005_CR44","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1128\/AAC.46.9.2996-3000.2002","volume":"46","author":"MM Gerrits","year":"2002","unstructured":"Gerrits MM, De Zoete MR, Arents NLA, Kuipers EJ, Kusters JG. 16S rRNA mutation-mediated tetracycline resistance in Helicobacter pylori. Antimicrob Agents Chemother. 2002;46:2996\u20133000. https:\/\/doi.org\/10.1128\/AAC.46.9.2996-3000.2002.","journal-title":"Antimicrob Agents Chemother"},{"key":"2005_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics13070643","author":"KA Guzman","year":"2024","unstructured":"Guzman KA, Hidalgo A, Pazos AJ. Point mutations in furazolidone and rifampicin resistance genes in Helicobacter pylori strains from Colombia. Antibiotics (Basel). 2024;13:643.\u00a0https:\/\/doi.org\/10.3390\/antibiotics13070643.","journal-title":"Antibiotics"},{"issue":"4","key":"2005_CR46","doi-asserted-by":"publisher","DOI":"10.1007\/s42770-023-01133-9","volume":"54","author":"P Zhao","year":"2023","unstructured":"Zhao P, Zhao J, Shi H, et al. Relationship between antibiotic resistance and the cagA and vacA genotypes among Helicobacter pylori strain isolates from patients in Xi\u2019an. Braz J Microbiol. 2023;54:2773. https:\/\/doi.org\/10.1007\/s42770-023-01133-9.","journal-title":"Braz J Microbiol"},{"issue":"1","key":"2005_CR47","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s13346-025-01986-7","volume":"16","author":"M Saha","year":"2026","unstructured":"Saha M, Gupta A, Kunkalienkar S, et al. Nanoemulsion as a promising drug delivery strategy for effective eradication of Helicobacter pylori: current insights. Drug Deliv Transl Res. 2026;16:17\u201344. https:\/\/doi.org\/10.1007\/s13346-025-01986-7.","journal-title":"Drug Deliv Transl Res"},{"key":"2005_CR48","doi-asserted-by":"publisher","DOI":"10.1128\/mmbr.00001-18","author":"S Hathroubi","year":"2018","unstructured":"Hathroubi S, Servetas SL, Windham I, Merrell DS, Ottemann KM. Helicobacter pylori biofilm formation and its potential role in pathogenesis.\u00a0Microbiol Mol Biol Rev. 2018;82:e00001-18.\u00a0https:\/\/doi.org\/10.1128\/mmbr.00001-18.\u00a0","journal-title":"Microbiol Mol Biol Rev"},{"key":"2005_CR49","doi-asserted-by":"publisher","unstructured":"Krzy\u017cek P. Helicobacter pylori efflux pumps: A double-edged sword in antibiotic resistance and biofilm formation. Int J Mol Sci. 2024;25:12222. https:\/\/doi.org\/10.3390\/ijms252212222.","DOI":"10.3390\/ijms252212222"},{"issue":"1","key":"2005_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-024-03816-y","volume":"22","author":"A Salahi-Niri","year":"2024","unstructured":"Salahi-Niri A, Nabavi-Rad A, Monaghan TM, et al. Global prevalence of Helicobacter pylori antibiotic resistance among children in the world health organization regions between 2000 and 2023: a systematic review and meta-analysis. BMC Med. 2024;22:598-. https:\/\/doi.org\/10.1186\/s12916-024-03816-y.","journal-title":"BMC Med"},{"key":"2005_CR51","doi-asserted-by":"publisher","unstructured":"Jearth V, Rath MM, Chatterjee A, Kale A, Panigrahi MK. Drug-resistant Helicobacter pylori: Diagnosis and evidence-based approach.\u00a0Diagnostics (Basel). 2023;13:2944.\u00a0https:\/\/doi.org\/10.3390\/diagnostics13182944.","DOI":"10.3390\/diagnostics13182944"},{"issue":"29","key":"2005_CR52","doi-asserted-by":"publisher","first-page":"9912","DOI":"10.3748\/wjg.v20.i29.9912","volume":"20","author":"SM Smith","year":"2014","unstructured":"Smith SM, O\u2019Morain C, McNamara D. Antimicrobial susceptibility testing for Helicobacter pylori in times of increasing antibiotic resistance. World J Gastroenterol. 2014;20:9912\u201321. https:\/\/doi.org\/10.3748\/wjg.v20.i29.9912.","journal-title":"World J Gastroenterol"},{"key":"2005_CR53","doi-asserted-by":"publisher","unstructured":"Patel RI, Shah C, Chauhan N, Upadhyay U. Gastro-retentive drug delivery systems: modern insights on approaches and applications. Int J Gastrointest Interv. 2025;14:43\u201350. https:\/\/doi.org\/10.18528\/IJGII240061.","DOI":"10.18528\/IJGII240061"},{"key":"2005_CR54","doi-asserted-by":"publisher","unstructured":"Zhao S, Lv Y, Bin ZJ, et al. Gastroretentive drug delivery systems for the treatment of Helicobacter pylori. World J Gastroenterol. 2014;20:9321\u20139. https:\/\/doi.org\/10.3748\/WJG.V20.I28.9321.","DOI":"10.3748\/WJG.V20.I28.9321"},{"key":"2005_CR55","doi-asserted-by":"publisher","unstructured":"Gupta A, Saha M, Kunkalienkar SS, et al. Design and characterization of novel gastroretentive drug delivery system of antibiotics and piperine for the eradication of H. pylori infection. Mol Pharm. 2025;22:7641\u201363. https:\/\/doi.org\/10.1021\/ACS.MOLPHARMACEUT.5C01253.","DOI":"10.1021\/ACS.MOLPHARMACEUT.5C01253"},{"key":"2005_CR56","doi-asserted-by":"publisher","unstructured":"Mosallam FM, Bendary MM, Elshimy R, El-Batal AI. Curcumin clarithromycin nano-form a promising agent to fight Helicobacter pylori infections.\u00a0World J Microbiol Biotechnol. 2023;39:324. https:\/\/doi.org\/10.1007\/S11274-023-03745-7.","DOI":"10.1007\/S11274-023-03745-7"},{"key":"2005_CR57","doi-asserted-by":"publisher","unstructured":"Safarov T, Kiran B, Bagirova M, Allahverdiyev AM, Abamor ES.\u00a0An overview of nanotechnology-based treatment approaches against Helicobacter Pylori. Expert Rev Anti Infect Ther. 2019;17:829\u201340. https:\/\/doi.org\/10.1080\/14787210.2019.1677464.","DOI":"10.1080\/14787210.2019.1677464"},{"key":"2005_CR58","doi-asserted-by":"publisher","unstructured":"Shariati A, Chegini Z, Ghaznavi-Rad E,\u00a0Zare EN, Hosseini SM.\u00a0PLGA-based nanoplatforms in drug delivery for inhibition and destruction of microbial biofilm.\u00a0Front Cell Infect Microbiol. 2022;12:926363. https:\/\/doi.org\/10.3389\/FCIMB.2022.926363.","DOI":"10.3389\/FCIMB.2022.926363"},{"key":"2005_CR59","doi-asserted-by":"publisher","unstructured":"Guo Z, Hou Y, Tian Y,\u00a0Tian J, Hu J, Zhang Y.\u00a0Antimicrobial peptide hydrogel with ph-responsive and controllable drug release properties for the efficient treatment of helicobacter pylori infection. ACS Appl Mater Interfaces. 2024;16:51981\u201393. https:\/\/doi.org\/10.1021\/ACSAMI.4C09185.","DOI":"10.1021\/ACSAMI.4C09185"},{"key":"2005_CR60","doi-asserted-by":"publisher","unstructured":"Juthi AZ, Li F, Wang B,\u00a0Alam MM, Talukder ME, Qiu B.\u00a0pH-responsive super-porous hybrid hydrogels for gastroretentive controlled-release drug delivery. Pharmaceutics. 2023;15:816. https:\/\/doi.org\/10.3390\/PHARMACEUTICS15030816.","DOI":"10.3390\/PHARMACEUTICS15030816"},{"key":"2005_CR61","doi-asserted-by":"publisher","unstructured":"Cinteza LO, Scomoroscenco C, Voicu SN, et al. Chitosan-stabilized ag nanoparticles with superior biocompatibility and their synergistic antibacterial effect in mixtures with essential oils. Nanomaterials. 2018;8:826. https:\/\/doi.org\/10.3390\/NANO8100826.","DOI":"10.3390\/NANO8100826"},{"key":"2005_CR62","doi-asserted-by":"publisher","unstructured":"Yin X, Lai Y, Du Y,\u00a0Zhang T, Gao J, Li Z. Metal-Based Nanoparticles: A Prospective Strategy for Helicobacter pylori Treatment. Int J Nanomedicine. 2023;18:2413\u201329. https:\/\/doi.org\/10.2147\/IJN.S405052.","DOI":"10.2147\/IJN.S405052"},{"key":"2005_CR63","doi-asserted-by":"publisher","unstructured":"Alfei S, Schito GC, Schito AM, Zuccari G. Reactive oxygen species (ROS)-mediated antibacterial oxidative therapies: Available methods to generate ros and a novel option proposal. Int J Mol Sci. 2024;25:7182. https:\/\/doi.org\/10.3390\/IJMS25137182.","DOI":"10.3390\/IJMS25137182"},{"key":"2005_CR64","doi-asserted-by":"publisher","unstructured":"Lin YH, Lin JH, Chou SC, et al. Berberine-loaded targeted nanoparticles as specific Helicobacter pylori eradication therapy: in vitro and in vivo study. Nanomedicine (Lond). 2015;10:57\u201371. https:\/\/doi.org\/10.2217\/NNM.14.76.","DOI":"10.2217\/NNM.14.76"},{"key":"2005_CR65","doi-asserted-by":"publisher","unstructured":"Zarzosa-Moreno D, Avalos-G\u00f3mez C, Ram\u00edrez-Texcalco LS, et al. Lactoferrin and its derived peptides: an alternative for combating virulence mechanisms developed by pathogens.\u00a0Molecules. 2020;25:5763. https:\/\/doi.org\/10.3390\/MOLECULES25245763.","DOI":"10.3390\/MOLECULES25245763"},{"key":"2005_CR66","doi-asserted-by":"publisher","unstructured":"Liu T, Chai S, Li M, et al. A nanoparticle-based sonodynamic therapy reduces Helicobacter pylori infection in mouse without disrupting gut microbiota. Nat Commun. 2024;15:844. https:\/\/doi.org\/10.1038\/s41467-024-45156-8.","DOI":"10.1038\/s41467-024-45156-8"},{"key":"2005_CR67","doi-asserted-by":"publisher","unstructured":"Mammari N, Duval RE. Photothermal\/photoacoustic therapy combined with metal-based nanomaterials for the treatment of microbial infections. Microorganisms. 2023;11:2084. https:\/\/doi.org\/10.3390\/MICROORGANISMS11082084.","DOI":"10.3390\/MICROORGANISMS11082084"},{"key":"2005_CR68","doi-asserted-by":"publisher","unstructured":"Qiao Y, Ma Y, Tong Y, et al. Phototherapy and mechanism exploration of biofilm and multidrug-resistant helicobacter pylori by bacteria-targeted NIR photosensitizer.\u00a0Small. 2023;19:e2205248.\u00a0https:\/\/doi.org\/10.1002\/SMLL.202205248.","DOI":"10.1002\/SMLL.202205248"},{"key":"2005_CR69","doi-asserted-by":"publisher","unstructured":"Im BN, Shin H, Lim B, et al. Helicobacter pylori-targeting multiligand photosensitizer for effective antibacterial endoscopic photodynamic therapy.\u00a0Biomaterials. 2021;271:120745. https:\/\/doi.org\/10.1016\/j.biomaterials.2021.120745.","DOI":"10.1016\/j.biomaterials.2021.120745"},{"key":"2005_CR70","doi-asserted-by":"publisher","unstructured":"Capurro MI, Prashar A, Jones NL. MCOLN1\/TRPML1 inhibition - a novel strategy used by Helicobacter pylori to escape autophagic killing and antibiotic eradication therapy in vivo. Autophagy. 2020;16:169\u201370. https:\/\/doi.org\/10.1080\/15548627.2019.1677322.","DOI":"10.1080\/15548627.2019.1677322"},{"key":"2005_CR71","doi-asserted-by":"publisher","unstructured":"Elshenawi Y, Hu S, Hathroubi S. Biofilm of helicobacter pylori: Life cycle, features, and treatment options. Antibiotics (Basel). 2023;12:1260. https:\/\/doi.org\/10.3390\/ANTIBIOTICS12081260.","DOI":"10.3390\/ANTIBIOTICS12081260"},{"key":"2005_CR72","doi-asserted-by":"publisher","unstructured":"Mei Z, Yuan J, Li D. Biological activity of galacto-oligosaccharides: A review. Front Microbiol. 2022;6:993052. https:\/\/doi.org\/10.3389\/FMICB.2022.993052\/TEXT.","DOI":"10.3389\/FMICB.2022.993052\/TEXT"},{"key":"2005_CR73","doi-asserted-by":"publisher","unstructured":"Yang Z, Zhou Y, Han Z, et al. The effects of probiotics supplementation on Helicobacter pylori standard treatment: an umbrella review of systematic reviews with meta-analyses. Sci Rep. 2024;14:10069. https:\/\/doi.org\/10.1038\/S41598-024-59399-4.","DOI":"10.1038\/S41598-024-59399-4"},{"key":"2005_CR74","doi-asserted-by":"publisher","unstructured":"Baryshnikova NV, Ilina AS, Ermolenko EI,\u00a0Uspenskiy YP, Suvorov AN. Probiotics and autoprobiotics for treatment of Helicobacter pylori infection. World J Clin Cases. 2023;11:4740\u201351. https:\/\/doi.org\/10.12998\/WJCC.V11.I20.4740.","DOI":"10.12998\/WJCC.V11.I20.4740"},{"key":"2005_CR75","doi-asserted-by":"publisher","unstructured":"Mu\u00f1oz AB, Stepanian J, Trespalacios AA, Vale FF. Bacteriophages of Helicobacter pylori. Front Microbiol. 2020;12:549084. https:\/\/doi.org\/10.3389\/FMICB.2020.549084\/TEXT.","DOI":"10.3389\/FMICB.2020.549084\/TEXT"},{"key":"2005_CR76","doi-asserted-by":"publisher","unstructured":"Tandoro Y, Chen BK, Ali A, Wang CK. Review of phytochemical potency as a natural anti-helicobacter pylori and neuroprotective agent. Molecules. 2023;28:7150. https:\/\/doi.org\/10.3390\/MOLECULES28207150.","DOI":"10.3390\/MOLECULES28207150"},{"key":"2005_CR77","doi-asserted-by":"publisher","unstructured":"Li G, Miao Z, Liu X,\u00a0Wang Q, Zheng X. Four novel anti-adhesive activity peptides against Helicobacter pylori derived from rice bran protein: release, identification and anti-adhesive mechanisms elucidation. Food Funct. 2024;15:8418\u201331. https:\/\/doi.org\/10.1039\/D4FO01734J.","DOI":"10.1039\/D4FO01734J"},{"key":"2005_CR78","doi-asserted-by":"publisher","unstructured":"Shaalan H, Azrad M, Peretz A. The effect of three urease inhibitors on H. pylori viability, urease activity and urease gene expression. Front Microbiol. 2024;15:1464484. https:\/\/doi.org\/10.3389\/FMICB.2024.1464484\/TEXT.","DOI":"10.3389\/FMICB.2024.1464484\/TEXT"},{"key":"2005_CR79","doi-asserted-by":"publisher","unstructured":"Gong H, Wang X, Hu X, et al. Effective treatment of helicobacter pylori infection using supramolecular antimicrobial peptide hydrogels. Biomacromolecules. 2024;25:1602\u201311. https:\/\/doi.org\/10.1021\/ACS.BIOMAC.3C01141.","DOI":"10.1021\/ACS.BIOMAC.3C01141"},{"key":"2005_CR80","doi-asserted-by":"publisher","unstructured":"Boyanova L, Gergova G, Markovska R,\u00a0Yordanov D, Mitov I.\u00a0Bacteriocin-like inhibitory activities of seven Lactobacillus delbrueckii subsp. bulgaricus strains against antibiotic susceptible and resistant Helicobacter pylori strains. Lett Appl Microbiol. 2017;65:469\u201374. https:\/\/doi.org\/10.1111\/LAM.12807.","DOI":"10.1111\/LAM.12807"},{"key":"2005_CR81","doi-asserted-by":"publisher","unstructured":"Choudhury A, Ortiz PS, Young M, et al. Control of Helicobacter pylori with engineered probiotics secreting selective guided antimicrobial peptides. Microbiol Spectr. 2023;11:e0201423. https:\/\/doi.org\/10.1128\/SPECTRUM.02014-23.","DOI":"10.1128\/SPECTRUM.02014-23"},{"key":"2005_CR82","doi-asserted-by":"publisher","unstructured":"Czinn SJ, Blanchard T. Vaccinating against Helicobacter pylori infection. Nat Rev Gastroenterol Hepatol. 2011;8:133\u201340. https:\/\/doi.org\/10.1038\/NRGASTRO.2011.1.","DOI":"10.1038\/NRGASTRO.2011.1"},{"key":"2005_CR83","doi-asserted-by":"publisher","unstructured":"Cui M, Ji X, Guan F,\u00a0Su G, Du L.\u00a0Design of a Helicobacter pylori multi-epitope vaccine based on immunoinformatics. Front Immunol. 2024;23:1432968. https:\/\/doi.org\/10.3389\/FIMMU.2024.1432968\/TEXT.","DOI":"10.3389\/FIMMU.2024.1432968\/TEXT"},{"key":"2005_CR84","doi-asserted-by":"publisher","unstructured":"Duque X, Moran S, Mera R, et al. Effect of eradication of helicobacter pylori and iron supplementation on the iron status of children with iron deficiency. Arch Med Res. 2010;41:38\u201345. https:\/\/doi.org\/10.1016\/j.arcmed.2009.11.006.","DOI":"10.1016\/j.arcmed.2009.11.006"},{"key":"2005_CR85","doi-asserted-by":"publisher","unstructured":"Ibrahim NH, Abdulhussien AA, Murtadha A,\u00a0Mohsein OA.\u00a0CRISPR-Cas systems in helicobacter pylori: A dual role in genome stability and pathogenesis.\u00a0American Journal of Biology and Natural Sciences. 2025;2:151\u201375. https:\/\/doi.org\/10.51699\/AJBNS.V2I5.1024.","DOI":"10.51699\/AJBNS.V2I5.1024"},{"key":"2005_CR86","doi-asserted-by":"publisher","unstructured":"Alum EU, Gulumbe BH, Izah SC, et al. Natural product-based inhibitors of quorum sensing: A novel approach to combat antibiotic resistance. Biochem Biophys Rep. 2025;43:102111. https:\/\/doi.org\/10.1016\/j.bbrep.2025.102111.","DOI":"10.1016\/j.bbrep.2025.102111"},{"key":"2005_CR87","doi-asserted-by":"publisher","unstructured":"Mackieh R, Al-Bakkar N, Kfoury M,\u00a0Roufayel R, Sabatier JM, Fajloun Z.\u00a0Inhibitors of ATP synthase as new antibacterial candidates.\u00a0Antibiotics (Basel). 2023;12:650. https:\/\/doi.org\/10.3390\/ANTIBIOTICS12040650.","DOI":"10.3390\/ANTIBIOTICS12040650"},{"key":"2005_CR88","doi-asserted-by":"publisher","unstructured":"Reza MN, Mahmud S, Ferdous N, et al. Gene silencing of Helicobacter pylori through newly designed siRNA convenes the treatment of gastric cancer. Cancer Med. 2023;12:22407\u201319. https:\/\/doi.org\/10.1002\/CAM4.6772.","DOI":"10.1002\/CAM4.6772"},{"key":"2005_CR89","doi-asserted-by":"publisher","unstructured":"Fakharian F, Asgari B, Nabavi-Rad A, et al. The interplay between Helicobacter pylori and the gut microbiota: An emerging driver influencing the immune system homeostasis and gastric carcinogenesis. Front Cell Infect Microbiol. 2022:12:953718. https:\/\/doi.org\/10.3389\/FCIMB.2022.953718.","DOI":"10.3389\/FCIMB.2022.953718"},{"key":"2005_CR90","doi-asserted-by":"publisher","unstructured":"Park JM, Han YM, Hahm KB. Rejuvenation of helicobacter pylori\u2013associated atrophic gastritis through concerted actions of placenta-derived mesenchymal stem cells prevented gastric cancer. Front Pharmacol. 2021;12:675443. https:\/\/doi.org\/10.3389\/FPHAR.2021.675443\/PDF.","DOI":"10.3389\/FPHAR.2021.675443\/PDF"},{"key":"2005_CR91","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/J.JCONREL.2019.02.039","volume":"300","author":"P Li","year":"2019","unstructured":"Li P, Chen X, Shen Y, et al. Mucus penetration enhanced lipid polymer nanoparticles improve the eradication rate of Helicobacter pylori biofilm. J Control Release. 2019;300:52\u201363. https:\/\/doi.org\/10.1016\/J.JCONREL.2019.02.039.","journal-title":"J Control Release."},{"key":"2005_CR92","doi-asserted-by":"publisher","first-page":"1418129","DOI":"10.3389\/FMICB.2024.1418129\/FULL","volume":"15","author":"TT Huang","year":"2024","unstructured":"Huang TT, Cao YX, Cao L. Novel therapeutic regimens against Helicobacter pylori: an updated systematic review. Front Microbiol. 2024;15:1418129. https:\/\/doi.org\/10.3389\/FMICB.2024.1418129\/FULL.","journal-title":"Front Microbiol."},{"key":"2005_CR93","doi-asserted-by":"publisher","unstructured":"Lina TT, Alzahrani S, Gonzalez J,\u00a0Pinchuk IV, Beswick EJ, Reyes VE. Immune evasion strategies used by Helicobacter pylori. World J Gastroenterol. 2014;20:12753\u201366. https:\/\/doi.org\/10.3748\/WJG.V20.I36.12753.","DOI":"10.3748\/WJG.V20.I36.12753"},{"issue":"1","key":"2005_CR94","doi-asserted-by":"publisher","first-page":"9891","DOI":"10.1007\/s00253-020-10945-w","volume":"104","author":"P Roszczenko-Jasi\u0144ska","year":"2020","unstructured":"Roszczenko-Jasi\u0144ska P, Wojty\u015b MI, Jagusztyn-Krynicka EK. Helicobacter pylori treatment in the post-antibiotics era-searching for new drug targets. Appl Microbiol Biotechnol. 2020;104:9891\u2013905. https:\/\/doi.org\/10.1007\/s00253-020-10945-w.","journal-title":"Appl Microbiol Biotechnol"},{"key":"2005_CR95","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10091028","author":"E Resina","year":"2021","unstructured":"Resina E, Gisbert JP. Rescue therapy with furazolidone in patients with at least five eradication treatment failures and multi-resistant H. pylori infection.\u00a0Antibiotics (Basel). 2021;10:1028.\u00a0https:\/\/doi.org\/10.3390\/antibiotics10091028.","journal-title":"Antibiotics (Basel)"},{"key":"2005_CR96","unstructured":"The efficacy of moxifloxacin-based triple-therapy in first-line treatment of Helicobacter pylori infection in Pakistan: randomized controlled trials [Internet]. [cited 2026 March 18]. Available from: https:\/\/www.termedia.pl\/The-efficacy-of-moxifloxacin-based-triple-therapy-r-nin-first-line-treatment-of-Helicobacter-pylori-infection-r-nin-Pakistan-randomized-controlled-trials,101,51608,1,1.html"},{"key":"2005_CR97","doi-asserted-by":"publisher","unstructured":"Cherdtrakulkiat R, Lawung R, Nabu S, et al. Nitroxoline: a potent antimicrobial agent against multidrug resistant Enterobacteriaceae. EXCLI J. 2019;18:445\u201353. https:\/\/doi.org\/10.17179\/excli2019-1378.\u00a0","DOI":"10.17179\/excli2019-1378"},{"key":"2005_CR98","doi-asserted-by":"publisher","DOI":"10.3390\/diseases10040090","author":"S Bernhard","year":"2022","unstructured":"Bernhard S, Kaiser M, Burri C, M\u00e4ser P. Fexinidazole for human African trypanosomiasis, the fruit of a successful public-private partnership.\u00a0Diseases. 2022;10:90. https:\/\/doi.org\/10.3390\/diseases10040090.","journal-title":"Diseases (Basel)"},{"key":"2005_CR99","doi-asserted-by":"publisher","unstructured":"Ishibashi F, Suzuki S, Nagai M, Mochida K, Morishita T. Optimizing Helicobacter pylori treatment: An updated review of empirical and susceptibility test-based treatments. Gut Liver. 2023;17:684\u201397. https:\/\/doi.org\/10.5009\/gnl220429.","DOI":"10.5009\/gnl220429"},{"issue":"1","key":"2005_CR100","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1111\/apt.13414","volume":"42","author":"DR Scott","year":"2015","unstructured":"Scott DR, Munson KB, Marcus EA, Lambrecht NWG, Sachs G. The binding selectivity of vonoprazan (TAK-438) to the gastric H+, K+ -ATPase. Aliment Pharmacol Ther. 2015;42:1315\u201326. https:\/\/doi.org\/10.1111\/apt.13414.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"2005_CR101","doi-asserted-by":"publisher","first-page":"135","DOI":"10.5114\/pg.2024.139426","volume":"19","author":"M Elsabaawy","year":"2024","unstructured":"Elsabaawy M, Shaban A, Al-Arab AE, Elbahr O, Edrees A, Afify S. Vonoprazan a novel potassium competitive acid blocker; another leap forward. Prz Gastroenterol. 2024;19:135\u201342. https:\/\/doi.org\/10.5114\/pg.2024.139426.","journal-title":"Prz Gastroenterol"},{"key":"2005_CR102","doi-asserted-by":"publisher","unstructured":"Chey WD, M\u00e9graud F, Laine L, L\u00f3pez LJ, Hunt BJ, Howden CW. Vonoprazan triple and dual therapy for Helicobacter pylori infection in the United States and Europe: Randomized clinical trial. Gastroenterology. 2022;163:608\u201319. https:\/\/doi.org\/10.1053\/j.gastro.2022.05.055.","DOI":"10.1053\/j.gastro.2022.05.055"},{"issue":"12","key":"2005_CR103","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.1111\/jgh.15700","volume":"36","author":"C Bunchorntavakul","year":"2021","unstructured":"Bunchorntavakul C, Buranathawornsom A. Randomized clinical trial: 7-day vonoprazan-based versus 14-day omeprazole-based triple therapy for Helicobacter pylori. J Gastroenterol Hepatol. 2021;36:3308\u201313. https:\/\/doi.org\/10.1111\/jgh.15700.","journal-title":"J Gastroenterol Hepatol"},{"issue":"5","key":"2005_CR104","doi-asserted-by":"publisher","first-page":"729","DOI":"10.3346\/jkms.2017.32.5.729","volume":"32","author":"S Park","year":"2017","unstructured":"Park S, Hyun YJ, Kim YR, et al. Effects of CYP2C19 genetic polymorphisms on PK\/PD responses of omeprazole in Korean healthy volunteers. J Korean Med Sci. 2017;32:729\u201336. https:\/\/doi.org\/10.3346\/jkms.2017.32.5.729.","journal-title":"J Korean Med Sci"},{"key":"2005_CR105","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12121669","author":"SI Smith","year":"2023","unstructured":"Smith SI, Yamaoka Y. Antibiotic resistance and therapy for Helicobacter pylori infection. Antibiotics (Basel). 2023;12:1669. https:\/\/doi.org\/10.3390\/antibiotics12121669.","journal-title":"Antibiotics"},{"key":"2005_CR106","doi-asserted-by":"publisher","unstructured":"Malfertheiner P, Megraud F, Rokkas T, et al. Management of Helicobacter pylori infection: the Maastricht VI\/Florence consensus report.\u00a0Gut. 2022:gutjnl-2022-327745. https:\/\/doi.org\/10.1136\/gutjnl-2022-327745.","DOI":"10.1136\/gutjnl-2022-327745"},{"issue":"12","key":"2005_CR107","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1097\/MEG.0000000000000197","volume":"26","author":"M Martos","year":"2014","unstructured":"Martos M, Bujanda L, Salicio Y, et al. Clarithromycin for first-line treatment of Helicobacter pylori infection after culture in high-resistance regions. Eur J Gastroenterol Hepatol. 2014;26:1380\u20134. https:\/\/doi.org\/10.1097\/MEG.0000000000000197.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"5","key":"2005_CR108","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/S0016-5085(98)70100-3","volume":"115","author":"DY Graham","year":"1998","unstructured":"Graham DY. Antibiotic resistance in Helicobacter pylori: implications for therapy. Gastroenterology. 1998;115:1272\u20137. https:\/\/doi.org\/10.1016\/S0016-5085(98)70100-3.","journal-title":"Gastroenterology"},{"key":"2005_CR109","doi-asserted-by":"publisher","unstructured":"Gupta A, Shetty S, Mutalik S, et al. Treatment of H. pylori infection and gastric ulcer: Need for novel pharmaceutical formulation. Heliyon. 2023;9:e20406. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e20406.","DOI":"10.1016\/j.heliyon.2023.e20406"},{"key":"2005_CR110","doi-asserted-by":"publisher","unstructured":"Iman M, Mirfakhraee S. Novel drug delivery systems for combating H. pylori: A brief review. Arch Razi Inst. 2024;79:903\u201314. https:\/\/doi.org\/10.32592\/ARI.2024.79.5.903.","DOI":"10.32592\/ARI.2024.79.5.903"},{"key":"2005_CR111","doi-asserted-by":"publisher","unstructured":"Ierardi E, Losurdo G, Mileti A, et al. The puzzle of coccoid forms of Helicobacter pylori: Beyond basic science. Antibiotics (Basel). 2020;9:293. https:\/\/doi.org\/10.3390\/antibiotics9060293.","DOI":"10.3390\/antibiotics9060293"},{"key":"2005_CR112","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2215777120","author":"M Xu","year":"2023","unstructured":"Xu M, Zhong XZ, Huang P, et al. TRPML3\/BK complex promotes autophagy and bacterial clearance by providing a positive feedback regulation of mTOR via PI3P. Proc Natl Acad Sci U S A. 2023;120:e2215777120. https:\/\/doi.org\/10.1073\/pnas.2215777120.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2005_CR113","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.rmed.2016.06.015","volume":"117","author":"F Blasi","year":"2016","unstructured":"Blasi F, Page C, Rossolini GM, et al. The effect of N-acetylcysteine on biofilms: implications for the treatment of respiratory tract infections. Respir Med. 2016;117:190\u20137. https:\/\/doi.org\/10.1016\/j.rmed.2016.06.015.","journal-title":"Respir Med"},{"key":"2005_CR114","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms12101986","author":"CMA Savitri","year":"2024","unstructured":"Savitri CMA, Fauzia KA, Alfaray RI, et al. Opportunities for Helicobacter pylori eradication beyond conventional antibiotics. Microorganisms. 2024;12:1986. https:\/\/doi.org\/10.3390\/microorganisms12101986.","journal-title":"Microorganisms"},{"issue":"1","key":"2005_CR115","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrd.2017.162","volume":"17","author":"SHE Kaufmann","year":"2018","unstructured":"Kaufmann SHE, Dorhoi A, Hotchkiss RS, Bartenschlager R. Host-directed therapies for bacterial and viral infections. Nat Rev Drug Discov. 2018;17:35\u201356. https:\/\/doi.org\/10.1038\/nrd.2017.162.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"2005_CR116","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1159\/000368232","volume":"7","author":"D Rizzuti","year":"2015","unstructured":"Rizzuti D, Ang M, Sokollik C, et al. Helicobacter pylori inhibits dendritic cell maturation via interleukin-10-mediated activation of the signal transducer and activator of transcription 3 pathway. J Innate Immun. 2015;7:199\u2013211. https:\/\/doi.org\/10.1159\/000368232.","journal-title":"J Innate Immun"},{"issue":"5","key":"2005_CR117","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","volume":"29","author":"Y Shiravand","year":"2022","unstructured":"Shiravand Y, Khodadadi F, Kashani SMA, et al. Immune checkpoint inhibitors in cancer therapy. Curr Oncol. 2022;29:3044\u201360. https:\/\/doi.org\/10.3390\/curroncol29050247.","journal-title":"Curr Oncol"},{"key":"2005_CR118","doi-asserted-by":"publisher","unstructured":"Marcotte H, Hammarstr\u00f6m L. Passive immunization: toward magic bullets.\u00a0Mucosal Immunology. 2015:1403\u201334. https:\/\/doi.org\/10.1016\/B978-0-12-415847-4.00071-9.","DOI":"10.1016\/B978-0-12-415847-4.00071-9"},{"key":"2005_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114985","author":"M Zhao","year":"2023","unstructured":"Zhao M, Chu J, Feng S, et al. Immunological mechanisms of inflammatory diseases caused by gut microbiota dysbiosis: A review.\u00a0Biomed Pharmacother. 2023;164:114985. https:\/\/doi.org\/10.1016\/j.biopha.2023.114985.","journal-title":"Biomed Pharmacother"}],"container-title":["Indian Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12664-026-02005-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12664-026-02005-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12664-026-02005-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T10:53:03Z","timestamp":1781261583000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12664-026-02005-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":119,"alternative-id":["2005"],"URL":"https:\/\/doi.org\/10.1007\/s12664-026-02005-4","relation":{},"ISSN":["0254-8860","0975-0711"],"issn-type":[{"value":"0254-8860","type":"print"},{"value":"0975-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"6 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors fully consent to the publication of the article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}},{"value":"MS, SS, BP, BM, NN and SM declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors are solely responsible for the data and the contents of the paper. In no way, the\u00a0Honorary Editor-in-Chief, Editorial Board Members, the Indian Society of Gastroenterology\u00a0or the printer\/publishers are responsible\u00a0for the results\/findings and content of this article.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}